Everolimus in advanced solid tumors: when to start, early or late?

Area of Science:

• Oncology
• Pharmacology

Background:

• Everolimus is an oral rapamycin derivative and a signal transduction inhibitor.
• It targets the mammalian target of rapamycin (mTOR) pathway, crucial for cell growth and angiogenesis.
• Approved indications include pancreatic neuroendocrine tumors (pNETs), metastatic renal cell carcinoma (mRCC), and breast carcinoma.

Purpose of the Study:

• To evaluate the optimal timing for initiating everolimus treatment.
• To explore the potential benefits of intermittent everolimus use in long-responding patients.
• To suggest personalized optimization of everolimus therapy based on patient and disease characteristics.

Main Methods:

• Analysis of data from three phase III randomized placebo-controlled trials (RADIANT-3, RECORD 1, BOLERO 2).
• Assessment of progression-free survival as the primary endpoint.
• Consideration of factors influencing treatment efficacy and patient outcomes.

Main Results:

• Everolimus demonstrated a statistically significant increase in median progression-free survival across all three trials.
• No significant overall survival benefit was observed, potentially due to trial design and subsequent therapies.
• The efficacy of everolimus was established in pNETs, mRCC, and breast carcinoma.

Conclusions:

• Everolimus effectively improves progression-free survival in specific advanced cancers.
• Further research is warranted on optimal treatment timing and intermittent dosing strategies.
• Personalized approaches considering patient and disease factors may enhance everolimus therapy outcomes.